Edgar Filing: RIGEL PHARMACEUTICALS INC - Form 4

RIGEL PHA Form 4 May 28, 201	ARMACEUTICA	ALS INC	-						
FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 4 or			S SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Section 16(a) of the Securities Exchange Act of 1934,				N OMB Number: Expires: Estimated burden hou response	Number: 3235-028 Number: January 31 Expires: 2005 Estimated average burden hours per response 0.5	
may con <i>See</i> Instr 1(b).	lunue.			•	•	ny Act of 1		011	
(Print or Type	Responses)								
1. Name and A DELEAGE	2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last) (First) (Middle) C/O RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD.			3. Date of Earliest Transaction(Month/Day/Year)05/28/2010			X_Director10% Owner Officer (give titleOther (specify below) below)			
(Street) SOUTH SAN			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
	CO, CA 94080						1013011		
(City)	(State)	(Zip)	Tab	ole I - Non-l	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	ally Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3,	(A) or of (D)	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Reminder: Re	port on a separate lin	e for each cl	ass of sec	urities bene	ficially ow	ned directly	or indirectly.		
					inforı requi	nation cont red to resp	spond to the colle tained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

number.

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Date, if TransactionDerivative Code Securities		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8 I S (1
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 6.73	05/28/2010		А	15,000	<u>(1)</u>	05/28/2020	Common Stock	15,000	

Edgar Filing: RIGEL PHARMACEUTICALS INC - Form 4

Reporting Owners

Reporting Owner Name / Address		Relationships					
Televing of the Linne (Linne (Dir	ector	10% Owner	Officer	Other		
DELEAGE JEAN C/O RIGEL PHARMACEUTICALS, IN 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080		X					
Signatures							
/s/ Dolly Vance (Attorney-In-Fact)	05/28/20)10					
**Signature of Reporting Person	Date						

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares vest monthly for twelve (12) months from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.